Blood Advances

Papers
(The H4-Index of Blood Advances is 64. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism601
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer403
American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19299
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma259
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma235
ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease233
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma218
A neutrophil activation signature predicts critical illness and mortality in COVID-19218
American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults196
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma189
First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab186
American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain171
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies157
ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease144
High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma133
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma130
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML122
Diversity of peripheral blood human NK cells identified by single-cell RNA sequencing119
Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub119
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma118
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients118
Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features114
The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19113
Reduced prevalence of SARS-CoV-2 infection in ABO blood group O112
Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1111
Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma110
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults105
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia101
RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML100
Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations99
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML99
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens98
Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-1994
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide92
Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease91
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease90
How much has allogeneic stem cell transplant–related mortality improved since the 1980s? A retrospective analysis from the EBMT89
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia89
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma88
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia 88
Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-1987
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML85
Gilteritinib: potent targeting of FLT3 mutations in AML85
Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge84
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML84
Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience83
Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura78
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure77
The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A76
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data76
Next-generation cell therapies: the emerging role of CAR-NK cells74
The critical role of CD4+ T cells in PD-1 blockade against MHC-II–expressing tumors such as classic Hodgkin lymphoma73
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality72
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial72
Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients70
Platelet-derived extracellular vesicles infiltrate and modify the bone marrow during inflammation69
Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study67
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis67
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States66
A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease66
Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma66
First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis65
Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease65
Artificial thymic organoids represent a reliable tool to study T-cell differentiation in patients with severe T-cell lymphopenia65
0.070220947265625